SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?
Abstract
:1. Introduction
2. Major Congenital Malformations and Cardiac Anomalies
3. Complications of Pregnancy
3.1. Spontaneous Abortions, Fetal and Perinatal Death
3.2. Prematurity and Intrauterine Growth Restriction (IUGR)
4. Neonatal Effects
4.1. Poor Neonatal Adaptation
4.2. Persistent Pulmonary Hypertension of the Newborn (PPHN)
5. Neurodevelopmental Effects
6. Possible Association with Autism Spectrum Disorder (ASD)
7. Epigenetic Changes
8. Pregnancy-Induced Changes in SRI Metabolism, Interaction with Genotype, Pharmacodynamics and Pharmacokinetic Changes
9. Future Research Directions and Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Berger, M.; Gray, J.A.; Roth, B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60, 355–366. [Google Scholar] [CrossRef]
- Brummelte, S.; Mc Glanaghy, E.; Bonnin, A.; Oberlander, T.F. Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation. Neuroscience 2017, 342, 212–231. [Google Scholar] [CrossRef] [Green Version]
- Oberlander, T.F. Fetal serotonin signaling: Setting pathways for early childhood development and behavior. J. Adolesc. Health. 2012, 51 (Suppl. 2), S9–S16. [Google Scholar] [CrossRef] [PubMed]
- Monti, J.M. Serotonin control of sleep-wake behavior. Sleep Med. Rev. 2011, 15, 269–281. [Google Scholar] [CrossRef] [PubMed]
- Diav-Citrin, O.; Ornoy, A. Selective serotonin reuptake inhibitors in human pregnancy: To treat or not to treat. Obstet. Gynecol. Int. 2012, 2012, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Huybrechts, K.F.; Bateman, B.T.; Palmsten, K.; Desai, R.J.; Patorno, E.; Gopalakrishnan, C.; Levin, R.; Mogun, H.; Hernandez-Diaz, S. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 2015, 313, 2142–2151. [Google Scholar] [CrossRef]
- Ornoy, A.; Koren, G. Selective serotonin reuptake inhibitors in human pregnancy: On the way to resolving the controversy. Semin. Fetal Neonatal Med. 2014, 19, 188–194. [Google Scholar] [CrossRef]
- Gingrich, J.A.; Malm, H.; Ansorge, M.S.; Brown, A.; Sourander, A.; Suri, D.; Teixeira, C.M.; Caffrey Cagliostro, M.K.; Mahadevia, D.; Weissman, M.M. New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain. Birth Defects Res. 2017, 109, 924–932. [Google Scholar] [CrossRef]
- Ornoy, A.; Koren, G. Selective Serotonin Reuptake Inhibitors during pregnancy: Do we have now more definite answers related to prenatal exposure. Birth Defects Res. Part C 2017, 109, 898–908. [Google Scholar] [CrossRef]
- Ornoy, A.; Koren, G. SSRIs use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects. Expert Opin. Drug Metab. Toxicol. 2018, 19, 1139–1145. [Google Scholar]
- Ramamoorthy, S.; Leibach, F.H.; Mahesh, V.B.; Ganapathy, V. Partial purification and characterization of the human placental serotonin transporter. Placenta 1993, 14, 449–461. [Google Scholar] [CrossRef]
- Rampono, J.; Simmer, K.; Ilett, K.F.; Hackett, L.P.; Doherty, D.A.; Elliot, R.; Kok, C.H.; Coenen, A.; Forman, T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009, 42, 95–100. [Google Scholar] [CrossRef] [PubMed]
- Wogelius, P.; Nørgaard, M.; Gislum, M.; Pedersen, L.; Munk, E.; Mortensen, P.B.; Lipworth, L.; Sørensen, H.T. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006, 17, 701–704. [Google Scholar] [CrossRef]
- Alwan, S.; Reefhuis, J.; Rassmussen, S.A.; Olney, R.S.; Friedman, J.M.; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and risk of birth defects. N. Engl. J. Med. 2007, 356, 2684–2692. [Google Scholar] [CrossRef]
- Diav-Citrin, O.; Shechtman, S.; Weinbaum, D.; Wajnberg, R.; Avgil, M.; Arnon, J.; Di Gianantonio, E.; Clementi, M.; Weber-Schoendorfer, C.; Schaefer, C.; et al. Paroxetine and Fluoxetine in Pregnancy: A prospective, multi-center, controlled, observational study. Br. J. Clin. Pharmacol. 2008, 66, 695–705. [Google Scholar] [PubMed]
- Huybrechts, K.F.; Hernández-Díaz, S.; Patorno, E.; Desai, R.J.; Mogun, H.; Dejene, S.Z.; Cohen, J.M.; Panchaud, A.; Cohen, L.; Bateman, B.T. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 2016, 73, 938–946. [Google Scholar] [CrossRef]
- Kornum, J.B.; Nielsen, R.B.; Pedersen, L.; Mortensen, P.B.; Nørgaard, M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin. Epidemiol. 2010, 2, 29–36. [Google Scholar] [CrossRef] [PubMed]
- Oberlander, T.F.; Warburton, W.; Misri, S.; Aghajanian, J.; Herzman, C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-Based health data. Birth Defects Res. B Dev. Reprod Toxicol. 2008, 83, 68–76. [Google Scholar] [CrossRef]
- Pedersen, L.H.; Henriksen, T.B.; Westergaard, M.; Olsen, J.; Bech, B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 2009, 339, b3569. [Google Scholar] [CrossRef]
- Jordan, S.; Morris, J.K.; Davies, G.I.; Tucker, D.; Thayer, D.S.; Luteijn, J.M.; Morgan, M.; Garne, E.; Hansen, A.V.; Klungsøyr, K.; et al. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. PLoS ONE 2016, 11, e0165122. [Google Scholar] [CrossRef]
- Knudsen, T.M.; Hansen, A.V.; Garne, E.; Andersen, A.M.Y. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data. BMC Pregnancy Child Birth 2014, 14, 333–341. [Google Scholar] [CrossRef] [PubMed]
- Daud, A.N.; Bergman, J.E.; Kerstjens-Frederikse, W.S.; Groen, H.; Wilffert, B. The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? Int. J. Mol. Sci. 2016, 17, 1333. [Google Scholar] [CrossRef]
- Bakker, M.K.; Kerstjens-Frederikse, W.S.; Buys, C.H.; de Walle, H.E.; de Jong-van den Berg, L.T. First trimester use of paroxetine and congenital heart defects: A population-based case-control study. Birth Defects Res. A Clin. Mol. Teratol. 2010, 88, 94–100. [Google Scholar] [CrossRef] [PubMed]
- Bérard, A.; Ramos, E.; Rey, E.; Blais, L.; St-André, M.; Oraichi, D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res. B Dev. Reprod. Toxicol. 2007, 80, 18–27. [Google Scholar] [CrossRef]
- Merlob, P.; Birk, E.; Sirota, L.; Linder, N.; Berant, M.; Stahl, B.; Klinger, G. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res. A Clin. Mol. Teratol. 2009, 85, 837–841. [Google Scholar] [CrossRef] [PubMed]
- Wemakor, A.; Casson, K.; Garne, E.; Bakker, M.; Addor, M.C.; Arriola, L.; Gatt, M.; Khoshnood, B.; Klungsoyr, K.; Nelen, V.; et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: A European register-based study. Eur. J. Epidemiol. 2015, 30, 1187–1198. [Google Scholar] [CrossRef]
- Källén, B.; Nilsson, E.; Olausson, P.O. Antidepressant use during pregnancy: Comparison of data obtained from a prescription register and from antenatal care records. Eur. J. Clin. Pharmacol. 2011, 67, 839–845. [Google Scholar] [CrossRef]
- Jimenez-Solem, E.; Andersen, J.T.; Petersen, M.; Broedbaek, K.; Jensen, J.K.; Afzal, S.; Gislason, G.H.; Torp-Pedersen, C.; Poulsen, H.E. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open 2012, 2, e001148. [Google Scholar] [CrossRef]
- Byatt, N.; Deligiannidis, K.M.; Freeman, M.P. Antidepressant use in pregnancy: A critical review focused on risks and controversies. Acta Psychiatr. Scand. 2013, 127, 94–114. [Google Scholar] [CrossRef]
- Louik, C.; Lin, A.E.; Werler, M.M.; Hernández-Díaz, S.; Mitchell, A.A. First-trimester use of selective serotonin-reuptake inhibitors and risk of birth defects. N. Engl. J. Med. 2007, 356, 2675–2683. [Google Scholar] [CrossRef]
- Kulin, N.A.; Pastuszak, A.; Sage, S.R.; Schick-Boschetto, B.; Spivey, G.; Feldkamp, M.; Ormond, K.; Matsui, D.; Stein-Schechman, A.K.; Cook, L.; et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 1998, 279, 609–610. [Google Scholar] [CrossRef]
- Malm, H.; Klaukka, T.; Neuvonen, P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol. 2005, 106, 1289–1296. [Google Scholar] [CrossRef]
- Hendrick, V.; Smith, L.M.; Suri, R.; Hwang, S.; Haynes, D.; Altshuler, L. Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. 2003, 188, 812–815. [Google Scholar] [CrossRef]
- Wichman, C.L.; Moore, K.M.; Lang, T.R.; St Sauver, J.L.; Heise, R.H., Jr.; Watson, W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc. 2009, 84, 23–40. [Google Scholar] [CrossRef]
- Bar-Oz, B.; Einarson, T.; Einarson, A.; Boskovic, R.; O’Brien, L.; Malm, H.; Bérard, A.; Koren, G. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin. Ther. 2007, 29, 918–926. [Google Scholar] [CrossRef] [PubMed]
- Wurst, K.E.; Poole, C.; Ephross, S.A.; Olshan, A.F. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res. A Clin. Mol. Teratol. 2010, 88, 159–170. [Google Scholar] [CrossRef]
- Scialli, A.R. Paroxetine exposure and during pregnancy and cardiac malformations. Birth Defects Res. A Clin. Mol. Teratol. 2010, 88, 175–177. [Google Scholar] [CrossRef] [PubMed]
- Gao, S.Y.; Wu, Q.J.; Sun, C.; Zhang, T.N.; Shen, Z.Q.; Liu, C.X.; Gong, T.T.; Xu, X.; Ji, C.; Huang, D.H.; et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: A systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018, 16, 205. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, L.; Einarson, T.R.; Sarkar, M.; Einarson, A.; Koren, G. Does paroxetine cause cardiac malformations? J. Obstet. Gynaecol. Can. 2008, 30, 696–701. [Google Scholar] [CrossRef]
- Addis, A.; Koren, G. Safety of fluoxetine during the first trimester of pregnancy; a meta-analytical review of epidemiological studies. Psychol. Med. 2000, 30, 89–94. [Google Scholar] [CrossRef]
- Einarson, T.R.; Einarson, A. Newer antidepressants and rates of major malformations; a meta-analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf. 2005, 14, 823–827. [Google Scholar] [CrossRef]
- Rahimi, R.; Nikfar, S.; Abdollahi, M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-analysis of clinical trials. Reprod. Toxicol. 2006, 22, 571–575. [Google Scholar] [CrossRef]
- Bérard, A.; Iessa, N.; Chaabane, S.; Muanda, F.T.; Boukhris, T.; Zhao, J.P. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2016, 81, 589–604. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Yang, L.; Wang, L.; Gao, L.; Xu, B.; Xiong, Y. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. J. Am. Heart Assoc. 2015, 4, e001681. [Google Scholar] [CrossRef] [PubMed]
- Shepard, T. “Proof” of human teratogenicity. Teratology 1994, 50, 97–98. [Google Scholar] [CrossRef] [Green Version]
- Brent, R.L. Environmental causes of human congenital malformations: The pediatrician’s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 2004, 113 (Suppl. 4), 957–968. [Google Scholar]
- Ban, L.; Tata, L.J.; West, J.; Fiaschi, L.; Gibson, J.E. Live and Non-Live Pregnancy Outcomes among Women with Depression and Anxiety: A Population-Based Study. PLoS ONE 2012, 7, e43462. [Google Scholar] [CrossRef]
- Einarson, A.; Choi, J.; Einarson, T.R.; Koren, G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J. Obstet. Gynaecol. Can. 2009, 31, 452–456. [Google Scholar] [CrossRef]
- Nakhai-Pour, H.R.; Broy, P.; Bérard, A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can. Med. Assoc. J. 2010, 182, 1031–1037. [Google Scholar] [CrossRef] [Green Version]
- Johansen, R.L.; Mortensen, L.H.; Andersen, A.M.; Hansen, A.V.; Strandberg-Larsen, K. Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage—Assessing potential biases. Paediatr. Perinat. Epidemiol. 2015, 29, 72–81. [Google Scholar] [CrossRef]
- Andersen, J.T.; Andersen, N.L.; Horwitz, H.; Poulsen, H.E.; Jimenez-Solem, E. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet. Gynecol. 2014, 124, 655–661. [Google Scholar] [CrossRef]
- Richardson, J.L.; Martin, F.; Dunstan, H.; Greenall, A.; Stephens, S.; Yates, L.M.; Thomas, S.H.L. Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study. Reprod. Toxicol. 2019, 84, 108–113. [Google Scholar] [CrossRef]
- Wen, S.W.; Yang, Q.; Garner, P.; Fraser, W.; Olatunbosun, O.; Nimrod, C.; Walker, M. Selective serotonin reuptake inhibitors and adverse pregnancy outcome. Am. J. Obstet. Gynecol. 2006, 194, 961–966. [Google Scholar] [CrossRef] [PubMed]
- Lund, N.; Pedersen, L.H.; Henriksen, T.B. Selective serotonin reuptake inhibitor exposure and pregnancy outcomes. Arch. Pediatr. Adolesc. Med. 2009, 163, 949–954. [Google Scholar] [CrossRef]
- Ramos, É.; St-André, M.; Bérard, A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can. J. Psychiatry 2010, 55, 643–652. [Google Scholar] [CrossRef] [PubMed]
- Calderon-Margalit, R.; Qiu, C.; Ornoy, A.; Siscovick, D.S.; Williams, M.A. Risks of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am. J. Obstet. Gynecol. 2009, 579, e1–e8. [Google Scholar] [CrossRef]
- Toh, S.; Mitchell, A.A.; Louik, C.; Werler, M.M.; Chambers, C.D.; Hernández-Díaz, S. antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J. Clin. Psychopharmacol. 2009, 29, 555–560. [Google Scholar] [CrossRef] [PubMed]
- Malm, H.; Sourander, A.; Gissler, M.; Gyllenberg, D.; Hinkka-Yli-Salomäki, S.; McKeague, I.W.; Artama, M.; Brown, A.S. Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results from Population-Based National Register Data. Am. J. Psychiatry 2015, 172, 1224–1232. [Google Scholar] [CrossRef]
- El Marroun, H.; Jaddoe, V.W.; Hudziak, J.J.; Roza, S.J.; Steegers, E.A.; Hofman, A.; Verhulst, F.C.; White, T.J.; Stricker, B.H.; Tiemeier, H. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch. Gen. Psychiatry 2012, 69, 706–714. [Google Scholar] [CrossRef]
- Zhao, X.; Liu, Q.; Cao, S.; Pang, J.; Zhang, H.; Feng, T.; Deng, Y.; Yao, J.; Li, H. A meta-analysis of selective serotonin reuptake inhibitors (SSRIs) use during prenatal depression and risk of low birth weight and small for gestational age. J. Affect. Disord. 2018, 241, 563–570. [Google Scholar] [CrossRef]
- Bonari, L.; Pinto, N.; Ahn, E.; Einarson, A.; Steiner, M.; Koren, G. Perinatal risks of untreated depression during pregnancy. Can. J. Psychiatry 2004, 49, 726–735. [Google Scholar] [CrossRef] [PubMed]
- Alder, J.; Fink, N.; Bitzer, J.; Hosli, I.; Holzgreve, W. Depression and anxiety during pregnancy; a risk factor for obstetric fetal and neonatal outcome? A critical review of the literature. J. Matern. Fetal Med. 2007, 20, 189–209. [Google Scholar] [CrossRef]
- Stahl, M.M.; Lindquist, M.; Pettersson, M.; Edwards, I.R.; Sanderson, J.H.; Taylor, N.F.; Fletcher, A.P.; Schou, J.S. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur. J. Clin. Pharmacol. 1997, 53, 163–169. [Google Scholar] [CrossRef]
- Zajecka, J.; Tracy, K.A.; Mitchell, S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J. Clin. Psychiatry 1997, 58, 291–297. [Google Scholar] [CrossRef] [PubMed]
- Källén, B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 2004, 158, 312–316. [Google Scholar] [CrossRef] [PubMed]
- Levinson-Castiel, R.; Merlob, P.; Linder, N.; Sirota, L.; Klinger, G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med. 2006, 160, 173–176. [Google Scholar] [CrossRef] [PubMed]
- Nörby, U.; Forsberg, L.; Wide, K.; Sjörs, G.; Winbladh, B.; Källén, K. Neonatal Morbidity after Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics 2016, 138, e20160181. [Google Scholar] [CrossRef]
- Chambers, C.D.; Hernandez-Diaz, S.; Van Marter, L.J.; Werler, M.M.; Louik, C.; Jones, K.L.; Mitchell, A.A. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 2006, 354, 579–587. [Google Scholar] [CrossRef] [PubMed]
- Källén, B.; Otterblad-Olausson, P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 2008, 17, 801–806. [Google Scholar] [CrossRef]
- Andrade, S.E.; McPhillips, H.; Loren, D.; Raebel, M.A.; Lane, K.; Livingston, J.; Boudreau, D.M.; Smith, D.H.; Davis, R.L.; Willy, M.E.; et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 2009, 18, 246–252. [Google Scholar] [CrossRef]
- Wilson, K.L.; Zelig, C.M.; Harvey, J.P.; Cunningham, B.S.; Dolinsky, B.M.; Napolitano, P.G. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol. 2011, 28, 19–24. [Google Scholar] [CrossRef]
- Bérard, A.; Sheehy, O.; Zhao, J.P.; Zhao, J.P.; Vinet, É.; Bernatsky, S.; Abrahamowicz, M. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br. J. Clin. Pharmacol. 2017, 83, 1126–1133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masarwa, R.; Bar-Oz, B.; Gorelik, E.; Reif, S.; Perlman, A.; Matok, I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: A systematic review, meta-analysis, and network meta-analysis. Am. J. Obstet. Gynecol. 2019, 220, e1–e57. [Google Scholar] [CrossRef]
- Klinger, G.; Frankenthal, D.; Merlob, P.; Diamond, G.; Sirota, L.; Levinson-Castiel, R.; Linder, N.; Stahl, B.; Inbar, D. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J. Perinatol. 2011, 9, 615–620. [Google Scholar] [CrossRef] [PubMed]
- Ornoy, A. The impact of intrauterine exposure versus postnatal environment in neurodevelopment toxicity: Long term neurobehavioral studies in children at risk for developmental disorders. Toxicol. Lett. 2003, 140/141, 171–181. [Google Scholar] [CrossRef]
- Ornoy, A.; Michailevskaya, V.; Lukashov, I.; Bar-Hamburger, R.; Harel, S. The developmental outcome of children born to heroin dependent mothers, raised at home or adopted. Child Abuse Neglect. 1996, 20, 385–396. [Google Scholar] [CrossRef]
- Ornoy, A.; Segal, J.; Bar-Hamburger, R.; Greenbaum, C. The developmental outcome of school age children born to heroin- dependent mothers: Importance of environmental factors. Dev. Med. Child. Neurol. 2001, 43, 668–675. [Google Scholar] [CrossRef] [PubMed]
- Ornoy, A. Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data. Reprod. Toxicol. 2017, 72, 191–200. [Google Scholar] [CrossRef]
- Nulman, I.; Rovet, J.; Stewart, D.E.; Wolpin, J.; Gardner, H.A.; Theis, J.G.; Kulin, N.; Koren, G. Neurodevelopment of children exposed in utero to antidepressants drugs. N. Eng. J. Med. 1997, 336, 258–262. [Google Scholar] [CrossRef]
- Nulman, I.; Rovet, J.; Stewart, D.E.; Wolpin, J.; Pace-Asciak, P.; Shuhaiber, S.; Koren, G. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective controlled study. Am. J. Psychiatry 2002, 159, 1889–1895. [Google Scholar] [CrossRef]
- Nulman, I.; Koren, G.; Rovet, J.; Barrera, M.; Pulver, A.; Streiner, D.; Feldman, B. Neurodevelopment of children following prenatal exposure to venlafaxine, selected serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 2012, 169, 1165–1174. [Google Scholar] [CrossRef]
- Nulman, I.; Koren, G.; Rovet, J.; Barrera, M.; Streiner, D.L.; Feldman, B.M. Neurodevelopment of children prenatally exposed to selective serotonin reuptake inhibitor antidepressants: Toronto sibling study. J. Clin. Psychiatry 2015, 76, e842–e847. [Google Scholar] [CrossRef]
- Misri, S.; Reebye, P.; Kendrick, K.; Carter, D.; Ryan, D.; Grunau, R.E.; Oberlander, T.F. Internalizing behaviors in 4-year old children exposed in-utero to psychotropic medications. Am. J. Psychiatry 2006, 163, 1026–1032. [Google Scholar] [CrossRef]
- Oberlander, T.F.; Reebye, P.; Misri, S.; Rapsdorf, M.; Kim, J.; Grunau, R.E. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 2007, 161, 22–29. [Google Scholar] [CrossRef]
- Casper, R.C.; Fleisher, B.E.; Lee-Ancajas, J.C.; Gilles, A.; Gaylor, E.; DeBattista, A.; Hoyme, H.E. Follow up of children of depressed mothers exposed or not exposed to antidepressants drugs during pregnancy. J. Pediatr. 2003, 142, 402–408. [Google Scholar] [CrossRef]
- Pedersen, L.H.; Henriksen, T.B.; Olsen, J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010, 125, e600–e608. [Google Scholar] [CrossRef]
- Hanley, G.E.; Brain, U.; Oberlander, T.F. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum. Dev. 2013, 89, 519–524. [Google Scholar] [CrossRef]
- Santucci, A.K.; Singer, L.T.; Wisniewski, S.R.; Luther, J.F.; Eng, H.F.; Dills, J.L.; Hanusa, B.H.; Wisner, K.L. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J. Clin. Psychiatry 2014, 75, 1088–1095. [Google Scholar] [CrossRef]
- Johnson, K.C.; Smith, A.K.; Stowe, Z.N.; Newport, D.J.; Brennan, P.A. Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: Differences in language and behavior, but not cognitive function. J. Clin. Psychiatry 2016, 77, e176–e182. [Google Scholar] [CrossRef]
- Brown, A.S.; Gyllenberg, D.; Malm, H.; McKeague, I.W.; Hinkka-Yli-Salomäki, S.; Artama, M.; Gissler, M.; Cheslack-Postava, K.; Weissman, M.M.; Gingrich, J.A.; et al. Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring. JAMA Psychiatry 2016, 73, 1163–1170. [Google Scholar] [CrossRef]
- Malm, H.; Brown, A.S.; Gissler, M.; Gyllenberg, D.; Hinkka-Yli-Salomäki, S.; McKeague, I.W.; Weissman, M.; Wickramaratne, P.; Artama, M.; Gingrich, J.A.; et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: A National Register-Based Study. J. Am. Acad. Child Adolesc. Psychiatry 2016, 55, 359–366. [Google Scholar] [CrossRef]
- Kragholm, K.; Andersen, M.P.; Mortensen, R.N.; Bech, L.F.; Polcwiartek, C.; Rohde, C.; Torp-Pedersen, C.; Videbech, P.; Nielsen, J. Exposure to selective serotonin reuptake inhibitors in utero and early elementary school outcomes. Acta Psychiatr. Scand. 2018, 137, 481–490. [Google Scholar] [CrossRef]
- Harrington, R.A.; Lee, L.C.; Crum, R.M.; Zimmerman, A.W.; Hertz-Piccioto, I. Serotonin hypothesis of autism: Implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013, 6, 149–163. [Google Scholar] [CrossRef]
- Croen, L.A.; Grether, J.K.; Yoshida, C.K.; Odouli, R.; Hendrick, V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 2011, 68, 1104–1112. [Google Scholar] [CrossRef]
- Harrington, R.A.; Lee, L.C.; Crum, R.M.; Zimmerman, A.W.; Hertz-Picciotto, I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 2014, 133, e1241–e1248. [Google Scholar] [CrossRef]
- Boukhris, T.; Sheehy, O.; Mottron, L.; Bérard, A. Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children. JAMA Pediatr. 2016, 170, 117–124. [Google Scholar] [CrossRef]
- Clements, C.C.; Castro, V.M.; Blumenthal, S.R.; Rosenfield, H.R.; Murphy, S.N.; Fava, M.; Erb, J.L.; Churchill, S.E.; Kaimal, A.J.; Doyle, A.E.; et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol. Psychiatry 2015, 20, 727–734. [Google Scholar] [CrossRef]
- Castro, V.M.; Kong, S.W.; Clements, C.C.; Brady, R.; Kaima, A.J.; Doyle, A.E.; Robinson, E.B.; Churchill, S.E.; Kohane, I.S.; Perlis, R.H. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: A replication study. Transl. Psychiatry 2016, 6, e708–e713. [Google Scholar] [CrossRef]
- Rai, D.; Lee, B.K.; Dalman, C.; Golding, J.; Lewis, G.; Magnusson, C. Parental depression, maternal antidepressant use during pregnancy and risk of autism spectrum disorder; population based case-control study. BMJ 2013, 346, f2059. [Google Scholar] [CrossRef]
- Sullivan, S.; Rai, D.; Golding, J.; Zammit, S.; Steer, C. The association between autism spectrum disorder and psychotic experience in the Avon longitudinal study of parents and children (ALSPAC) birth cohort. J. Am. Acad. Child Adolesce. Psychiatry 2013, 52, 806–814. [Google Scholar] [CrossRef]
- Hviid, A.; Melbye, M.; Pasternak, B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N. Engl. J. Med. 2013, 369, 2406–2415. [Google Scholar] [CrossRef] [PubMed]
- Sørensen, M.J.; Grønborg, T.K.; Christensen, J.; Parner, E.T.; Vestergaard, M.; Schendel, D.; Pedersen, L.H. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin. Epidemiol. 2013, 15, 449–459. [Google Scholar] [CrossRef] [PubMed]
- Sujan, A.C.; Rickert, M.E.; Öberg, A.S.; Quinn, P.D.; Hernández-Díaz, S.; Almqvist, C.; Lichtenstein, P.; Larsson, H.; D’Onofrio, B.M. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA 2017, 317, 1553–1562. [Google Scholar] [CrossRef]
- Yang, F.; Chen, J.; Miao, M.H.; Yuan, W.; Li, L.; Liang, H.; Ehrenstein, V.; Li, J. Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: A population-based cohort study. BMJ Open 2017, 7, e016368. [Google Scholar] [CrossRef]
- Man, K.K.; Tong, H.H.; Wong, L.Y.; Chan, E.W.; Simonoff, E.; Wong, I.C. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neurosci. Biobehav. Rev. 2015, 49, 82–89. [Google Scholar] [CrossRef] [Green Version]
- Andalib, S.; Emamhadi, M.R.; Yousefzadeh-Chabok, S.; Shakouri, S.K.; Høilund-Carlsen, P.F.; Vafaee, M.S.; Michel, T.M. Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review. Eur. Psychiatry 2017, 45, 161–166. [Google Scholar] [CrossRef]
- Gentile, S. Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods? J. Affect. Disord. 2015, 182, 132–137. [Google Scholar] [CrossRef]
- Kaplan, Y.C.; Keskin-Arslan, E.; Acar, S.; Sozmen, K. Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis. Reprod. Toxicol. 2016, 66, 31–43. [Google Scholar] [CrossRef]
- Mezzacappa, A.; Lasica, P.A.; Gianfagna, F.; Cazas, O.; Hardy, P.; Falissard, B.; Sutter-Dallay, A.L.; Gressier, F. Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017, 171, 555–563. [Google Scholar] [CrossRef]
- Brown, H.K.; Hussain-Shamsy, N.; Lunsky, Y.; Dennis, C.E.; Vigod, S.N. The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: A Systematic Review and Meta-Analysis. J. Clin. Psychiatry 2017, 78, e48–e58. [Google Scholar] [CrossRef]
- Fatima, Z.; Zahra, A.; Ghouse, M.; Wang, X.; Yuan, Z. Maternal SSRIs experience and risk of ASD in offspring: A review. Toxicol. Res. 2018, 7, 1020–1028. [Google Scholar] [CrossRef]
- Ergaz, Z.; Fudim–Weinstein, L.; Ornoy, A. Genetic and non-genetic animal models for Autism Spectrum Disorders (ASD). Reprod. Toxicol. 2016, 64, 116–140. [Google Scholar] [CrossRef]
- Fuller, R.W. Mechanisms and functions of serotonin neuronal systems: Opportunities for neuropeptide interactions. Ann. N. Y. Acad. Sci. 1996, 780, 176–184. [Google Scholar] [CrossRef]
- Pariante, C.M. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann. N. Y. Acad. Sci. 2009, 1179, 144–152. [Google Scholar] [CrossRef]
- Juruena, M.F.; Cleare, A.J.; Pariante, C.M. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev. Bras. Pisquitr. 2004, 26, 189–201. [Google Scholar] [CrossRef]
- Nikisch, G. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function. Neuro Endocrinol. Lett. 2009, 30, 11–16. [Google Scholar]
- Reynolds, R.M. Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis-2012 Curt Richter Award Winner. Psychoneuroendocrinology 2013, 38, 1–11. [Google Scholar] [CrossRef]
- Brunton, P.J. Effects of maternal exposure to social stress during pregnancy: Consequences for mother and offspring. Reproduction 2013, 146, 175–189. [Google Scholar] [CrossRef]
- Petropoulos, S.; Guillemin, C.; Ergaz, Z.; Dimov, S.; Suderman, M.; Weinstein-Fudim, L.; Ornoy, A.; Szyf, M. Gestational Diabetes alters offspring DNA methylation profiles in human and rat: Identification of key genes involved in endocrine system disorders, insulin signaling, diabetes signaling and IL-K signaling pathways. Endocrinology 2015, 156, 2222–2238. [Google Scholar] [CrossRef]
- Ornoy, A.; Reece, A.E.; Pavlinkova, G.; Kappen, C.; Miller, R.K. Effect of maternal diabetes on the embryo, fetus and children: Congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res. Part C 2015, 105, 53–72. [Google Scholar] [CrossRef]
- Li, M.; D’Arcy, C.; Li, X.; Zhang, T.; Joober, R.; Meng, X. What do DNA methylation studies tell us about depression? A systematic review. Transl. Psychiatry 2019, 9, 68. [Google Scholar] [CrossRef]
- Flandreau, E.I.; Bourke, C.H.; Ressler, K.J.; Vale, W.W.; Nemeroff, C.B.; Owens, M.J. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. Psychoneuroendocrinology 2013, 38, 1349–1361. [Google Scholar] [CrossRef]
- Avitsur, R.; Grinshpahet, R.; Goren, N.; Weinstein, I.; Kirshenboim, O.; Chlebowski, N. Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: Possible role for glucocorticoid resistance. Horm. Behav. 2016, 84, 41–49. [Google Scholar] [CrossRef] [PubMed]
- Bourke, C.H.; Stowe, Z.N.; Neigh, G.N.; Olson, D.E.; Owens, M.J. Prenatal exposure to escitalopram and/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats. Neurotoxicol. Teratol. 2013, 39, 100–109. [Google Scholar] [CrossRef] [Green Version]
- Salari, A.A.; Fatehi-Gharehlar, L.; Motayagheni, N.; Homberg, J.R. Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring. Behav. Brain Res. 2016, 311, 354–356. [Google Scholar] [CrossRef] [PubMed]
- Pawluski, J.L.; Rayen, I.; Niessen, N.A.; Kristensen, S.; van Donkelaar, E.L.; Balthazart, J.; Steinbusch, H.W.; Charlier, T.D.L. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 2012, 220, 131–141. [Google Scholar] [CrossRef]
- Gurnot, C.; Martin-Subero, I.; Mah, S.M.; Weikum, W.; Goodman, S.J.; Brain, U.; Werker, J.F.; Kobor, M.S.; Esteller, M.; Oberlander, T.F.; et al. Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates. Epigenetics 2015, 10, 361–372. [Google Scholar] [CrossRef]
- Oberlander, T.F.; Grunau, R.; Mayes, L.; Riggs, W.; Rurak, D.; Papsdorf, M.; Misri, S.; Weinberg, J. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum. Dev. 2008, 84, 689–697. [Google Scholar] [CrossRef]
- Pawluski, J.L.; Brain, U.M.; Underhill, C.M.; Hammond, G.L.; Oberlander, T.F. Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology 2012, 37, 1019–1028. [Google Scholar] [CrossRef]
- Owen, J.R.; Nemeroff, C.B. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine. Depress. Anxiety. 1998, 7 (Suppl. 1), 24–32. [Google Scholar] [CrossRef]
- Hemeryck, A.; Belpaire, F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update. Curr. Drug Metab. 2002, 3, 13–37. [Google Scholar] [CrossRef] [PubMed]
- Knadler, M.P.; Lobo, E.; Chappell, J.; Bergstrom, R. Clinical pharmacokinetics and drug interactions. Clin. Pharmacokinet. 2011, 50, 281–294. [Google Scholar] [CrossRef]
- Preskorn, S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997, 32 (Suppl. 1), 1–21. [Google Scholar] [CrossRef]
- Donneyong, M.M.; Bykov, K.; Bosco-Levy, P.; Dong, Y.H.; Levin, R.; Gagne, J.J. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: Multi-database cohort study. BMJ 2016, 354, i5014. [Google Scholar] [CrossRef] [PubMed]
- Andrade, C. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J. Clin. Psychiatry 2014, 75, e95–e99. [Google Scholar] [CrossRef]
- Dong, Y.H.; Bykov, K.; Choudhry, N.K.; Huybrechts, K.F.; Levin, R.; Schneeweiss, S.; Gagne, J.J. Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study. J. Clin. Psychopharmacol. 2017, 37, 200–209. [Google Scholar] [CrossRef] [PubMed]
- Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; Müller, D.J.; Ji, Y.; Leckband, S.G.; Leeder, J.S.; Graham, R.L.; Chiulli, D.L.; LLerena, A.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC). Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther. 2015, 98, 127–134. [Google Scholar] [CrossRef]
- Ter Horst, P.G.; Larmené-Beld, K.H.; Bosman, J.; van der Veen, E.L.; Wieringa, A.; Smit, J.P. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J. Clin. Pharm. Ther. 2014, 39, 541–544. [Google Scholar] [CrossRef]
- Heikkinen, T.; Ekblad, U.; Palo, P.; Laine, K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin. Pharmacol. Ther. 2003, 73, 330–337. [Google Scholar] [CrossRef]
- Ke, A.B.; Nallani, S.C.; Zhao, P.; Rostami-Hodjegan, A.; Isoherranen, N.; Unadkat, J.D. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab. Dispos. 2013, 41, 801–813. [Google Scholar] [CrossRef]
- Ververs, F.F.; Voorbij, H.A.; Zwarts, P.; Belitser, S.V.; Egberts, T.C.; Visser, G.H.; Schobben, A.F. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin. Pharmacokinet. 2009, 48, 677–683. [Google Scholar] [CrossRef]
- Bérard, A.; Gaedigk, A.; Sheehy, O.; Chambers, C.; Roth, M.; Bozzo, P.; Johnson, D.; Kao, K.; Lavigne, S.; Wolfe, L.; et al. OTIS (MotherToBaby) Collaborative Research Committee. Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy. Front. Pharmacol. 2017, 8, 402. [Google Scholar] [CrossRef]
- Velasquez, J.C.; Goeden, N.; Herod, S.M.; Bonnin, A. Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy. ACS Chem. Neurosci. 2016, 7, 327–338. [Google Scholar] [CrossRef]
- Bennett, H.A.; Einarson, A.; Taddio, A.; Koren, G.; Einarson, T.R. Prevalence of depression during pregnancy: Systematic review. Obstet. Gynecol. 2004, 103, 698–709. [Google Scholar] [CrossRef]
- Berle, J.O.; Steen, V.M.; Aamo, T.O.; Breilid, H.; Zahlsen, K.; Spigset, O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: Infant exposure, clinical symptoms, and cytochrome p450 genotypes. J. Clin. Psychiatry 2004, 65, 1228–1234. [Google Scholar] [CrossRef]
- Oberlander, T.F.; Bonaguro, R.J.; Misri, S.; Papsdorf, M.; Ross, C.J.; Simpson, E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry 2008, 13, 65–73. [Google Scholar] [CrossRef]
Issue Studied | References | Results | Comments |
---|---|---|---|
Original studies looking at major congenital malformations | [13,14,15,16,17,18,19,20] | No increase | Consensus in most studies that, in general, there is no increase in the rate of major malformations |
Original studies looking at cardiac malformations | [15,21,22,23,24,25,26,28,29,30,31,32,33,34] | Possible increase of severe cardiac anomalies | Issue in debate: Large studies are generally positive, especially demonstrating an increase in rare, severe, cardiac malformations. Other studies have shown a similar increase in untreated mothers with depression |
Original studies looking at miscarriage and stillbirths | [15,47,48,49,50,51,52] | Generally no increase | The slight increase is related to maternal disease or gestational age at study |
Original studies looking at preterm birth and low birth weight | [49,52,53,54,55,56,57,58,59] | Generally no increase in preterm birth and no effects on fetal growth | The slight increase in preterm birth and possible decreased fetal growth are related to maternal disease |
Issue Studied | Reference | Results | Comments |
---|---|---|---|
Poor neonatal adaptation | [63,64,65,66,67] | SRI may interfere with neonatal adaptation | Present in up to 30% of newborn infants. Generally no long-term sequelae |
PPHN | [6,68,69,70,71,72] | SRI may increase the rate of PPHN | Less than 1%, not very severe, apparently no death reported |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ornoy, A.; Koren, G. SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers? Int. J. Mol. Sci. 2019, 20, 2370. https://doi.org/10.3390/ijms20102370
Ornoy A, Koren G. SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers? International Journal of Molecular Sciences. 2019; 20(10):2370. https://doi.org/10.3390/ijms20102370
Chicago/Turabian StyleOrnoy, Asher, and Gideon Koren. 2019. "SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?" International Journal of Molecular Sciences 20, no. 10: 2370. https://doi.org/10.3390/ijms20102370
APA StyleOrnoy, A., & Koren, G. (2019). SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers? International Journal of Molecular Sciences, 20(10), 2370. https://doi.org/10.3390/ijms20102370